| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8229880 | International Journal of Radiation Oncology*Biology*Physics | 2011 | 7 Pages |
Abstract
In our evaluation of nearly 100 patients with newly diagnosed GBM, treatment with adjuvant gefitinib post-radiation was not associated with significant improvement in OS or PFS. However, patients who experienced gefitinib-associated adverse effects (rash/diarrhea) did demonstrate improved OS.
Keywords
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Joon H. M.D., Karla V. Ph.D., Wenting Ph.D., Caterina M.D., J.C. M.D., Jan C. M.D., C.D. Ph.D., Bernd W. M.D., Robert J. M.D., Patrick J. M.D., Paul L. M.D., Shaker R. M.D., Kurt A. M.D.,